Wrong, the O/S is relatively unchanged @ roughly 110,000,000.
Wrong, the PPS is still trading higher than AEPP lows prior to the R/M.
Notes have been renegotiated with equity and interest accrued until Q2 2019.
Wrong. A relatively small note of $5.4 accrues interest @ a 10% annum with equity and interest accrued until Q2 2019
That is a given with a pre-revenue bio/pharma company engaged in FDA clinical trials.
Wrong. Results from the original cohort are in ONCX SEC filings and ONCX investor presentations. There are also ONCX CEO interviews available that cover this.
BioVectra (a subsidiary of Mallinckrodt PLC NYSE: MNK,) has been producing Prolanta and the former Biovectra CEO is an ONCX board member.
Wrong, the majority of compensation due to ONCX officers (roughly $1,200,000) has been deferred.
Wrong. The inventor of Prolanta, Dr. Chen was never an ONCX employee.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.